Investing.comCodex · 实盘不做把握 3/10
北京时间·🕒 发布 19:04:33时区推断·⟳ 抓取 19:16:21·⚡ 决策 08-04 22:53:10 +3h36m·83.8 天前
Labcorp在美国推出Roche获FDA批准的前列腺癌PTEN伴随诊断检测
Labcorp上线Roche的PTEN伴随诊断检测，方向上有利于其肿瘤检测服务组合完整性。
📄 原文Investing.com↗ 原文
Labcorp launches FDA-approved PTEN test for prostate cancer
U.S.-Iran talks uncertain; Palantir, Snap report - what’s moving markets BURLINGTON, N.C. - Labcorp (NYSE:LH) announced…
不做 Labcorp（LH.US）
单项伴随诊断检测上线属于常规产品菜单扩展，未披露金额、订单或能相对Labcorp整体收入形成短期重定价的增量，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-04 · 扩散 low · price-in 风险 low ↗
关键理由
- Labcorp上线Roche的PTEN伴随诊断检测，方向上有利于其肿瘤检测服务组合完整性。
主要风险
- 该检测未披露定价、订单或收入贡献，作为大型医学检验公司的新增单项检测，短线业绩弹性显然不足。
原文全文
展开原文 · 1,802 字
U.S.-Iran talks uncertain; Palantir, Snap report - what’s moving markets
BURLINGTON, N.C. - Labcorp (NYSE:LH) announced today the nationwide availability of Roche’s VENTANA PTEN (SP218) RxDx Assay, the first immunohistochemistry companion diagnostic test approved by the U.S. Food and Drug Administration to determine PTEN protein loss in tumors of patients with prostate adenocarcinoma.
The assay identifies patients who may be eligible for treatment with AstraZeneca’s TRUQAP (capivasertib) in combination with abiraterone acetate and prednisone, according to a press release statement.
PTEN is a tumor suppressor protein that regulates cell growth. Loss of PTEN protein expression has been associated with more aggressive disease progression in prostate cancer. Prostate cancer is the most common cancer among men in the United States excluding skin cancer, with more than 330,000 new cases expected annually.
The VENTANA PTEN (SP218) RxDx Assay detects PTEN protein loss in prostate cancer tissue specimens, providing clinicians with biomarker information for treatment decisions.
"Biomarker testing is essential to advancing precision oncology and helping connect patients with the therapies most appropriate for their disease," said Shakti Ramkissoon, vice president and medical lead for oncology at Labcorp.
Labcorp participated in Roche’s early access program to support laboratory readiness for the assay. The test is available through Labcorp’s national network of laboratories and can be ordered alongside the company’s portfolio of oncology testing services.
The assay complements Labcorp’s existing genomic, molecular and companion diagnostic testing services for oncology care.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
BURLINGTON, N.C. - Labcorp (NYSE:LH) announced today the nationwide availability of Roche’s VENTANA PTEN (SP218) RxDx Assay, the first immunohistochemistry companion diagnostic test approved by the U.S. Food and Drug Administration to determine PTEN protein loss in tumors of patients with prostate adenocarcinoma.
The assay identifies patients who may be eligible for treatment with AstraZeneca’s TRUQAP (capivasertib) in combination with abiraterone acetate and prednisone, according to a press release statement.
PTEN is a tumor suppressor protein that regulates cell growth. Loss of PTEN protein expression has been associated with more aggressive disease progression in prostate cancer. Prostate cancer is the most common cancer among men in the United States excluding skin cancer, with more than 330,000 new cases expected annually.
The VENTANA PTEN (SP218) RxDx Assay detects PTEN protein loss in prostate cancer tissue specimens, providing clinicians with biomarker information for treatment decisions.
"Biomarker testing is essential to advancing precision oncology and helping connect patients with the therapies most appropriate for their disease," said Shakti Ramkissoon, vice president and medical lead for oncology at Labcorp.
Labcorp participated in Roche’s early access program to support laboratory readiness for the assay. The test is available through Labcorp’s national network of laboratories and can be ordered alongside the company’s portfolio of oncology testing services.
The assay complements Labcorp’s existing genomic, molecular and companion diagnostic testing services for oncology care.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。